FIELD: chemistry; medicine.
SUBSTANCE: invention relates to organic and medical chemistry, namely to a combination of drugs for treating tumours mediated by FAK. Combination is characterized by that it contains a compound selected from compounds of formula 25, 41, 44, 45, 46, or a pharmaceutically acceptable salt thereof, and an immunotherapeutic drug in the same or different specified preparative forms for simultaneous or separate administration, and a pharmaceutically acceptable carrier. Immunotherapeutic agent is a PD-1 inhibitor.
EFFECT: creation of new combinations containing a compound having inhibitory activity on FAK, and an immunotherapeutic agent representing a PD-1 inhibitor, which can find application in medicine for treating FAK-mediated tumours.
4 cl, 2 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DEUTERATED DEFACTINIB COMPOUNDS AND THEIR APPLICATION | 2019 |
|
RU2761825C1 |
| COMPOUNDS WITH SPIRO AND AROMATIC RINGS AND APPLICATION THEREOF | 2019 |
|
RU2781100C1 |
| PROTEINKINASE INHIBITORS, METHOD FOR OBTAINING THEREOF AND MEDICAL APPLICATION | 2016 |
|
RU2749437C2 |
| DYETERED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH CONNECTIONS | 2014 |
|
RU2632907C2 |
| PYRROLOPYRIMIDINE COMPOUNDS AND APPLICATION THEREOF | 2011 |
|
RU2563644C2 |
| POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF | 2014 |
|
RU2655921C2 |
| PHTHALAZINE KETONE DERIVATIVE, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL APPLICATION | 2011 |
|
RU2564527C2 |
| KINASE INHIBITORS, PRODRUG FORMS THEREOF AND USE THEREOF IN THERAPY | 2010 |
|
RU2568639C2 |
| HALOGEN-SUBSTITUTED PHENYLATE COMPOUND AND USE THEREOF | 2020 |
|
RU2820475C2 |
| SELECTIVE INHIBITORS OF Haspin kinase | 2012 |
|
RU2548363C2 |
